RxDoctor Payments Data

Solomon Kuchipudi, MD

Internal Medicine · Somerset, NJNPI 1073544284

Payments from drug & device makers

$6,893in general payments, 2019–2025

Across 404 payments — averaging $17.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AstraZeneca$1K
  • AbbVie$876
  • Lilly USA, LLC$461
  • Abbott$439
  • Amgen$383
  • plus $2K from 12 others

What the payments were for

  • Food & beverage$6,76998%
  • Education$1242%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,893 in reported general payments places this provider in the 90th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$250,093
Medicare patients
93
Services billed
2,161

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin53$48,680
OzempicSemaglutide24$32,796
JanumetSitagliptin Phos/Metformin Hcl37$27,138
EliquisApixaban28$24,352
FarxigaDapagliflozin Propanediol13$18,442
LinzessLinaclotide20$13,038
BrilintaTicagrelor16$6,771
Xigduo XrDapaglifloz Propaned/Metformin11$6,243
Memantine Hcl43$3,389
Rosuvastatin Calcium133$2,094
Ezetimibe40$1,813
Metoprolol Succinate116$1,740
Omega-3 Acid Ethyl Esters14$1,402
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide14$1,391
Nateglinide25$1,340

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$115$48,68053 claims
Novo NordiskOzempic$1,493$32,79624 claims
MerckJanumet$168$27,13837 claims
AstraZenecaFarxiga, Brilinta$1,491$25,21429 claims
PfizerEliquis$147$24,35228 claims
AbbVieLinzess$876$13,03820 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Somerset

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →